SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kerala Ayurveda - Quaterly Results

27 May 2025 Evaluate
The company witnessed a 13.01% growth in the revenue at Rs. 193.45 millions for the quarter ended March 2025 as compared to Rs. 171.18 millions during the year-ago period.The Net Loss for the quarter ended March 2025 is Rs. -118.64 millions as compared to Net Loss of Rs. -3.94 millions of corresponding quarter ended March 2024Operating profit Margin for the quarter ended March 2025 slipped to -66.20% as compared to 36.22% of corresponding quarter ended March 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 193.45 171.18 13.01 726.89 680.36 6.84 726.89 680.36 6.84
Other Income 43.74 30.03 45.65 51.71 30.07 71.97 51.71 30.07 71.97
PBIDT -66.20 36.22 -282.77 -74.16 68.05 -208.98 -74.16 68.05 -208.98
Interest 28.05 30.81 -8.96 39.16 53.98 -27.45 39.16 53.98 -27.45
PBDT -94.25 0.11 -85781.82 -113.32 14.07 -905.40 -113.32 14.07 -905.40
Depreciation 14.56 10.09 44.30 21.51 15.74 36.66 21.51 15.74 36.66
PBT -108.81 -9.98 990.28 -134.83 -1.67 7973.65 -134.83 -1.67 7973.65
TAX 9.83 -6.04 -262.75 2.98 -2.20 -235.45 2.98 -2.20 -235.45
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -118.64 -3.94 2911.17 -137.81 0.53 -26101.89 -137.81 0.53 -26101.89
Equity 120.32 120.32 0.00 120.32 120.32 0.00 120.32 120.32 0.00
PBIDTM(%) -34.22 21.16 -261.73 -10.20 10.00 -202.00 -10.20 10.00 -202.00

Kerala Ayurveda Share Price

245.35 3.10 (1.28%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×